ESMO E-Learning: Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines
- To summarise the current understandings and pitfalls in the diagnosis and staging of patients with malignant pleural mesothelioma and apply knowledge to define the best prognostic indicators
- To understand the treatment options for patients with malignant pleural mesothelioma and how best to integrate them into multimodality treatment schedule
- To select appropriate treatment strategies for patients with malignant pleural mesothelioma throughout the course of the disease
|Title||Duration||Content||CME Points||CME Test|
|Clinical Cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines||10 min.||22 slides||1||Take Test|
This presentation has been developed with the intention to discuss the clinical perspective of the ESMO guidelines for diagnosis, treatment and follow-up of patients with malignant pleural mesothelioma. The module consists of specific patient cases with descriptions of the clinical picture, findings from the physical examination, undertaken diagnostic procedure and presents the treatment options throughout the course of the disease.
Malignant pleural mesothelioma is a rare tumour. Within the next 20 years the incidence is estimated to double in many countries. Exposure to asbestos is a well-established aetiological factor for malignant pleural mesothelioma, with occupational exposure being documented in 70–80% of those affected.
In many European countries, due to the latency period, the numbers of cases are expected to rise until 2018/2020 and then they will decline again, but for countries with no legal restriction on asbestos exposure, there will probably be a continuous rise.
This E-learning module challenges the medical professional audience on questions such as selection of the best diagnostic procedure, optimal staging approach, and preferred treatment options in this particular case. It is truly a multidisciplinary clinical case, and therefore suitable for all professionals involved in the diagnosis, treatment and follow-up of patients with malignant pleural mesothelioma. It covers various topics, from surgical biopsies, histological diagnosis, to the first-line chemotherapy.
Furthermore, it follows the same patient in time. The patient is offered the opportunity to participate in a clinical trial, incorporating thoracic surgery in the treatment schedule and after progression the audience is challenged with the question on the role of radiotherapy in this particular disease.
Aiming to enhance experience with the ESMO guidelines material, we strongly recommend oncology professionals to refer to the full version of the guidelines text available in the Supplement of Annals of Oncology, as well as the guidelines section of the ESMO Website.
The author has reported no conflict of interest